logo BDSP

Base documentaire

  1. Economic evaluation of new treatments : Haematopoietic growth factors.

    Article - En anglais

    The clinical benefits of new healthcare interventions usually receive considerable attention, but their impact on the economic aspects of care provision are not so well considered.

    Among the issues that different audiences will want to see addressed are : how clinical benefits translate into resource use savings in practice ; the extent to which clinical trial outcomes can be said to be representative or normal practice and the value of the economic impact to purchasers and providers.

    In this review we consider these elements using the haematopoietic growth factors as an example.

    Mots-clés Pascal : Facteur stimulant colonie granulocyte, Facteur stimulant colonie granulocyte macrophage, Facteur stimulant colonie, Anticancéreux, Association médicamenteuse, Tumeur maligne, Hémopathie maligne, Chimiothérapie, Traitement, Greffe, Cellule souche, Cellule hématopoïétique, Sang, Autogreffe, Analyse coût efficacité, Homme, Cytokine, Polypeptide, Transfusion, Economie santé

    Mots-clés Pascal anglais : Granulocyte colony stimulating factor, Granulocyte macrophage colony stimulating factor, Colony stimulating factor, Antineoplastic agent, Drug combination, Malignant tumor, Malignant hemopathy, Chemotherapy, Treatment, Graft, Stem cell, Hematopoietic cell, Blood, Autograft, Cost efficiency analysis, Human, Cytokine, Polypeptide, Transfusion, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0199705

    Code Inist : 002B02R02. Création : 199608.